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Introduction: Crizotinib and ceritinib have been developed
to treat advanced or metastatic NSCLC by inhibiting
anaplastic lymphoma receptor tyrosine kinase gene (ALK).
No randomized trial has compared these treatments head-
to-head. We compared efﬁcacy outcomes between patients
receiving ceritinib and an external control group receiving
crizotinib, both as initial ALK-targeted therapies for previ-
ously treated advanced or metastatic ALK-positive NSCLC.
Methods: Individual patient data for the ceritinib-treated
patients were drawn from two single-arm trials (ASCEND-1
and ASCEND-3); published summary data for the crizotinib-
treated patients were extracted from three trials (PROFILE
1001, PROFILE 1005, and PROFILE 1007). To adjust for
cross-trial differences, average baseline characteristics were
matched using propensity score weighting. Overall survival
(OS), progression-free survival (PFS), and overall response
rate were then compared between treatment groups.
Results: Before matching, the ceritinib-treated patients
(n ¼ 189) were signiﬁcantly different from the crizotinib-
treated patients (n ¼ 557) in the distribution of race and
number of prior regimens. After matching, all available
baseline characteristics were balanced. Compared with
crizotinib, ceritinib was associated with longer OS (hazard
ratio ¼ 0.59, 95% conﬁdence interval: 0.46–0.75) and
longer PFS (median 13.8 versus 8.3 months, hazard ratio ¼
0.52, 95% conﬁdence interval: 0.44–0.62) in Cox propor-
tional hazards models. The 12-month OS was 82.6% with
ceritinib and 66.0% with crizotinib in a Kaplan-Meier
analysis (log-rank p < 0.001). There was no signiﬁcantJournal of Thoracic Oncology Vol. 11 No. 9: 1550-1557difference in overall response rate between ceritinib and
crizotinib.
Conclusions: In an adjusted comparison across separate
clinical trials, ceritinib was associated with prolonged OS
and PFS compared with crizotinib when used as initial ALK-
targeted therapy for previously treated ALK-positive NSCLC.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: ALK; NSCLC; ceritinib; crizotinib; indirect
comparison
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Lung cancer is the worldwide leading cause of cancer
death and is typically diagnosed at an advanced stage.1,2
More than 85% of lung cancers are classiﬁed as NSCLC,3
for which chemotherapy is at best only moderately
active, with response rates of approximately 20%.4,5
Effective targeted therapies developed against speciﬁc
molecular subtypes of NSCLC such as EGFR and
anaplastic lymphoma receptor tyrosine kinase gene
(ALK) have further expanded the therapeutic opportu-
nities and have led to signiﬁcant improvement in
survival.6,7
Approximately 2% to 7% of patients with stage III or
IV NSCLC harbor ALK fusions.8 These patients tend to be
younger, associated with light or never-smoking status,
and have a propensity for development of brain metas-
tases.9,10 The occurrence of brain metastases is
estimated to be up to 50% in patients treated with ﬁrst-
generation ALK inhibitors.11 Two ALK-targeted thera-
pies, crizotinib and ceritinib, have been approved for the
treatment of ALK-positive NSCLC. Crizotinib has been
demonstrated to improve progression-free survival
(PFS) compared with chemotherapy in both the ﬁrst-
line12 (median PFS 10.9 months versus 7.0 months,
respectively) and second-line13 (median PFS 7.7 months
versus 3.0 months, respectively) settings. Ceritinib, a
second-generation ALK inhibitor, has been shown to be
effective in the treatment of advanced or metastatic ALK-
positive NSCLC, including for crizotinib-pretreated pa-
tients. In the phase I ASCEND-1 clinical trial, the overall
response rate (ORR) was 56.4% with a median PFS of 6.9
months among patients with prior use of crizotinib.14
Among crizotinib-naive patients, more than 70%
achieved ORR and the median PFS was 18.4 months.14
Recent studies have revealed potential differences in
efﬁcacy between these two ALK-targeted therapies.
According to preclinical data, ceritinib is 20 times as
potent as crizotinib against ALK.15 In addition, ceritinib
has been shown to be active in patients in whom resis-
tance to crizotinib has developed, with impressive tumor
responses observed in brain metastases.16,17 To date, no
randomized controlled trial (RCT) has compared crizo-
tinib and ceritinib, although each has been investigated
in multiple clinical trials.13,14,18–20 In the absence of
head-to-head RCTs, comparative efﬁcacy in advanced
oncology settings, including ALK-positive NSCLC, is often
based on comparisons with external controls.11,21–23 One
technique that can reduce bias in such comparisons is
the use of propensity score matching to achieve baseline
similarity across treatment groups. These steps include a
comparison of trial designs and study settings, selection
of patients based on shared inclusion/exclusion criteria,
and matching of multiple known baseline prognosticfactors on the basis of a propensity score model. Studies
reporting an estimated treatment effect derived by this
method have been supported by results from RCTs.24,25
The present study attempted to compare efﬁcacy
outcomes for ceritinib with those in an external control
population receiving crizotinib in two cohorts balanced
through propensity score matching. We then compared
the overall survival (OS), PFS, and ORR of patients
receiving ceritinib with those of the external comparator
receiving crizotinib, with both treatments used as the
initial ALK-targeted therapy for chemotherapy-treated
ALK-positive NSCLC.Materials and Methods
Study Populations and Data Sources
The evidence for the efﬁcacy of ceritinib and crizo-
tinib in crizotinib-naive advanced or metastatic
ALK-positive NSCLC is based on ﬁve clinical trials.
Two single-arm studies are available for ceritinib in
this population: the phase I trial ASCEND-114,20
(NCT01283516 [data cutoff date April 14, 2014]) and
the phase II trial ASCEND-326 (NCT01685138 [data
cutoff date June 27, 2014]). Three trials are available
for crizotinib, including the phase I single-arm study
PROFILE 100118 (NCT00585195 [data cutoff date
January 2, 2012]), the phase II single-arm study PROFILE
100519 (NCT00932451 [data cutoff date February 1,
2011]), and the phase III, open-label RCT of crizotinib
and chemotherapy PROFILE 100713 (NCT00932893
[data cutoff date March 30, 2012]). These data represent
the most recent, publically available crizotinib trial data
in which the relevant population and outcomes of
interest are reported. The doses assigned in the ceritinib
and crizotinib arms in these trials are consistent with
label recommendations (750 mg orally once daily for
ceritinib; 250 mg orally twice daily for crizotinib).
These ﬁve trials had generally consistent study
designs (Supplementary Table 1). All trials enrolled adult
patients with locally advanced or metastatic ALK-positive
NSCLC. Patients with stable or controlled brain metasta-
ses were allowed. Baseline Eastern Cooperative Oncology
Group performance status (ECOG PS) ranged between
0 and 2 within all studies except for PROFILE 1005, in
which approximately 17% of patients had a baseline
ECOG PS of 3. All trials allowed prior treatment for
advanced or metastatic ALK-positive NSCLC, but only
the ASCEND-3 and PROFILE 1001 trials speciﬁcally
excluded patients previously treated with ALK-targeted
agents. PROFILE 1005 allowed at least one prior
chemotherapy, and PROFILE 1007 trial allowed only one
prior platinum-based chemotherapy; the other trials did
not limit the number or type of prior systemic therapies.
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were obtained from Novartis Pharmaceuticals Corpora-
tion. IPD from the crizotinib trials were not publically
available, so published summary statistics from the cri-
zotinib trials were used in the current analyses. In
particular, data on baseline characteristics and response
rates were extracted from published literature and
publically available regulatory brieﬁng documents and
reports.27,28 Rates of OS and PFS at multiple time points
were extracted from published Kaplan-Meier curves
using Engauge Digitizer software29 and the approach
described in Guyot et al. 2012,30 which is consistent with
the National Institute for Health and Care Excellence
technical support guidelines.31
As a ﬁrst step toward harmonizing the study pop-
ulations receiving ceritinib and crizotinib, a shared set
of inclusion and exclusion criteria was applied to all
trials. All present analyses included data only from
patients who had (1) received at least one prior sys-
temic therapy and (2) not been previously treated with
an ALK-targeted agent. Thus, in the crizotinib trials,
published baseline characteristics and outcomes were
extracted speciﬁcally for the subgroup of previously
treated patients. In the ceritinib trials, IPD for all pre-
viously treated and crizotinib-naive patients were
included.Outcome Measures
OS, PFS, and ORR were deﬁned similarly across trials.
OS was deﬁned as the time from treatment initiation (or
from randomization for PROFILE 1007) to death due to
any cause. PFS was deﬁned as the time from treatment
initiation (or from randomization for PROFILE 1007) toFigure 1. Patient selection of pooled ceritinib- and crizotinib
treated patients were pooled from two single-arm trials (ASCE
efﬁcacy outcomes for crizotinib-treated patients were extracte
and PROFILE 1007). Previously treated patients without prior ex
(ALK)-targeted therapies were selected as the primary analysisdisease progression (deﬁned by Response Evaluation
Criteria in Solid Tumors [RECIST]) or death due to any
cause, whichever occurred ﬁrst. Durations of OS and PFS
in patients without observed events were censored at
the last day on which they were known to be event-free.
ORR was deﬁned as the proportion of patients with a
best overall complete response (CR) or partial response
(PR) determined by speciﬁed criteria (i.e., RECIST
version 1.0 for phase I trials, RECIST version 1.1 for
phase II and III trials).Statistical Methods
To assess comparability of the ceritinib-treated
population and the external control group receiving
crizotinib, baseline characteristics were compared
between these treatment groups. All baseline variables
that were available and consistently deﬁned in all trials
were included: age, sex, race, tumor histologic type
(e.g., adenocarcinoma), ECOG PS (0 versus 1), and
number of prior regimens (1, 2, or 3). Comparisons
were conducted using chi-square tests.
To make an adjusted comparison between the
ceritinib- and crizotinib-treated patients, propensity
score weighting was used to adjust for baseline differ-
ences between the populations.32,33 Speciﬁcally, indi-
vidual ceritinib-treated patients were assigned statistical
weights that adjusted for their overrepresentation or
underrepresentation relative to the crizotinib-treated
population such that after weighting, average baseline
characteristics were balanced between the treatment
groups. The statistical weights were based on a
propensity score model incorporating all available
baseline characteristics. The propensity score model-treated populations. Individual patient data for ceritinib-
ND-1 and ASCEND-3). Summary baseline characteristics and
d from three published studies (PROFILE 1001, PROFILE 1005,
posure to anaplastic lymphoma receptor tyrosine kinase gene
sample.
Table 1. Primary Analysis: Baseline Characteristics before
and after Matching
Baseline
Characteristics
Pooled Ceritinib
Population
Pooled Crizotinib
Population
Prematch
(n ¼ 189)
Postmatch
(n ¼ 189;
neff ¼ 143)
As Reported
(n ¼ 557)
Median age, y 55.0 52.0 52.0
Female 56.6 54.0 54.0
Asiana 55.0 37.6 37.6
ECOG performance
status of 0
34.9 32.2 32.2
No. prior regimensa
1 48.7 45.1 45.1
2 28.0 21.8 21.8
3 23.3 33.1 33.1
Adenocarcinoma 94.7 95.0 95.0
Note: Reported as percentages unless otherwise speciﬁed.
ap Values < 0.05 were considered statistically signiﬁcant for comparisons
between pooled ceritinib and crizotinib trials before matching.
neff, effective sample size after weighting; ECOG, Eastern Cooperative
Oncology Group.
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ceritinib-treated patients and the published summary
data available for the crizotinib-treated patients.34–36
After matching, efﬁcacy outcomes were compared
between balanced treatment groups using statistical
tests that incorporated the propensity score weights.
For OS and PFS, weighted Kaplan-Meier curves were
generated and compared using weighted log-
rank tests. Hazard ratios (HRs) comparing ceritinib
and crizotinib were estimated using weighted Cox
proportional hazards models. The proportionalTable 2. Primary Analysis: Comparisons of OS, PFS, and Respo
Efﬁcacy Outcomesa
Pooled Ceritinib Population
Prematch
(n ¼ 189)
[A]
Postmatch
(n ¼ 189; neff ¼
[B]
OS
Median, mo NR (19.6–NR) NR (19.6–NR)
1-year OS rate, % 83.5 (75.6–89.0) 82.6 (74.9–91.1)
HR (ceritinib vs. crizotinib) 0.49 (0.33–0.74) 0.59 (0.46–0.75)
PFS
Median, mo 13.8 (11.1–NR) 13.8 (11.1, NR)
1-year PFS rate, % 56.5 (47.5–67.1) 58.2 (47.9–70.7)
HR (ceritinib vs. crizotinib) 0.56 (0.43–0.73) 0.52 (0.44–0.62)
Response rate
ORR (CR þ PR), % 66.7 (59.9–73.4) 68.3 (60.8–75.7)
CR, % 0.0 0.0
PR, % 66.7 (59.9–73.4) 68.3 (60.8–75.7)
aRanges in parentheses are 95% conﬁdence intervals.
bp Values < 0.05 were considered statistically signiﬁcant for comparisons betw
OS, overall survival; PFS, progression-free survival; Neff, effective sample size af
CR, complete response; PR, partial response.hazards assumption was tested both before and after
matching. ORRs were compared using weighted chi-
square tests.
Four sensitivity analyses were conducted to explore
additional baseline adjustments involving ethnicity,
brain metastases, single-arm versus randomized trial
design, and smoking status. The ﬁrst sensitivity analysis
was conducted to match on the proportion of white
versus nonwhite patients, whereas the primary analysis
adjusted for the proportion of Asian versus non-Asian
patients because of a potentially higher response rate
to crizotinib among Asian patients revealed in previous
studies.11,18,37 In the present study, non-Asian and
nonwhite individuals comprised only 1% of ceritinib-
and 5% of crizotinib-treated patients. In the second
sensitivity analysis, the presence of baseline brain me-
tastases was additionally adjusted for considering brain
metastases as one of the prognostic factors associated
with poor outcomes in ALK-positive NSCLC. Because the
baseline information with brain metastases was not
available in PROFILE 1001, the second sensitivity
analysis included only the subset of crizotinib trials
(PROFILE 1005 and PROFILE 1007) that reported brain
metastases. The third sensitivity analysis excluded
PROFILE 1007, the only RCT included in the study (all
other trials were single-arm), to investigate potential
confounding of the external control group by randomi-
zation to chemotherapy. Lastly, given the impact of
smoking status on NSCLC clinical outcomes, the fourth
sensitivity analysis added smoking status at baseline to
the list of characteristics used for adjustment, excluding
the ASCEND-3 trial, in which data on smoking status
were not available.nse Rate before and after Matching
Pooled Crizotinib Population p Values
143)
As reported
(n ¼ 557)
[C] [A] vs. [C] [B] vs. [C]
20.5 (19.9–29.6)
66.0 (62.1–70.2) <0.001b <0.001b
Reference <0.001b <0.001b
8.3 (7.3–9.3)
37.2 (33.3–41.5) <0.001b <0.001b
Reference <0.001b <0.001b
61.2 (57.2–65.3) 0.181 0.102
1.4 (0.4–2.4) 0.098 0.010b
59.8 (55.7–63.9) 0.093 0.049b
een pooled ceritinib and crizotinib trials.
ter weighting; NR, not reached; HR, hazard ratio; ORR, overall response rate;
Figure 2. Overall survival (OS) and progression-free survival
(PFS) between balanced ceritinib- and crizotinib-treated
populations. (A) Kaplan-Meier estimates of OS after match-
ing adjustment. The median OS was not reached with cer-
itinib as compared with 20.5 months with crizotinib.
(B) Kaplan-Meier estimates of PFS after matching adjust-
ment. The median PFS was 13.8 months with ceritinib as
compared with 8.3 months with crizotinib. CI, conﬁdence
interval.
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(SAS Institute Inc., Cary, NC) and R 2.15.2 software
(R Foundation for Statistical Computing). Statistical sig-
niﬁcance was assessed at the 5% level.
Results
The pooled ceritinib trials included 189 patients who
had at least one prior systemic treatment and were naive
to ALK-targeted agents, including 67 patients from
ASCEND-1 and 122 fromASCEND-2. The pooled crizotinib
trials consisted of 557 previously treated patients,
including 125 patients from PROFILE 1001, 259 from
PROFILE 1005, and 173 randomized to the crizotinib arm
in PROFILE1007. Selection of the primary analysis sample
is described in Figure 1. Efﬁcacy outcomes in the included
trials are summarized in Supplementary Table 2.
Before matching, the ceritinib-treated patients
included a signiﬁcantly higher proportion of Asians(55.0% versus 37.6% [p < 0.001]) compared with the
crizotinib-treated patients. The distribution of number of
prior regimens was signiﬁcantly different between the
two populations, with more heavily pretreated patients
in the pooled crizotinib trials (p ¼ 0.028). After matching
adjustment, all baseline characteristics were exactly
balanced between the two populations (Table 1). After
weighting adjustment, the effective sample size for the
ceritinib-treated patients, which measures the statistical
information available after weighting, was 143 (the
number of actual subjects included in the analyses
remained 189 before and after weighting).
After matching, the 1-year OS rate was signiﬁcantly
higher among the ceritinib-treated patients than among
the crizotinib-treated patients (82.6% versus 66.0%
[p < 0.001]). Ceritinib was associated with a signiﬁcantly
lower hazard of death compared with crizotinib
(HR ¼ 0.59, 95% conﬁdence interval: 0.46–0.75)
(Table 2 and Fig. 2A). The 1-year PFS rate among the
ceritinib-treated patients was signiﬁcantly higher than
that among the crizotinib-treated patients after matching
(58.2% versus 37.2% [p < 0.001]). Ceritinib was also
associated with signiﬁcantly longer median PFS
compared with crizotinib (median 13.8 versus 8.3
months, HR ¼ 0.52, 95% conﬁdence interval: 0.44–0.62)
(Fig. 2B). Prematching analyses based on the unweighted
sample produced similar results for OS and PFS. The
proportional hazards assumption was validated for all
analyses of OS and PFS, both before and after matching.
Before matching, the patients who received ceritinib
had response rates similar to those of the patients who
received crizotinib, as measured by CR (0% versus 1.4%
[p ¼ 0.098]), PR (66.7% versus 59.8%, [p ¼ 0.093]), and
ORR (66.7% versus 61.2% [p ¼ 0.181]). After matching
adjustment, there was a signiﬁcant difference in CR (0%
in ceritinib versus 1.4% with crizotinib [p ¼ 0.010])
and PR (68.3% in ceritinib versus 59.8% with crizotinib,
[p ¼ 0.049]). ORR did not differ signiﬁcantly between
treatment groups.
The estimated comparative efﬁcacy of ceritinib and
crizotinib was consistent across the four sensitivity
analyses after additional baseline adjustment (Table 3).
In the ﬁrst sensitivity analysis, the prevalence of
whites was lower among the ceritinib population than
among the crizotinib population (43.9% versus 57.2%)
before matching and was exactly balanced at 57.2%
after matching adjustment. In the second sensitivity
analysis, the proportion of patients with brain metas-
tases at screening in the ceritinib treatment group was
more than double that in the crizotinib treatment
group (38.6% versus 18.0%) before matching but was
balanced at 18.0% in both groups after matching. In
the third sensitivity analysis, which was based only on
single-arm trials, the ceritinib-treated patients had a
Table 3. Sensitivity Analyses: Comparisons of OS and PFS before and after Matching
Additional Baseline Adjustment Criteria
HRs for Ceritinib vs. Crizotinib (95% CI)
Prematch Postmatch
1. Matching on prevalence of whites n ¼ 189 vs. n ¼ 557 p Value neff ¼ 152 vs. n ¼ 557 p Value
OS 0.49 (0.33–0.74) <0.001 0.58 (0.45–0.74) <0.001
PFS 0.56 (0.43–0.73) <0.001 0.53 (0.44–0.62) <0.001
2. Adjusting for baseline brain metastases
(excluding PROFILE 1001)
n ¼ 189 vs. n ¼ 432 neff ¼ 128 vs. n ¼ 432
OS 0.47 (0.32–0.71) <0.001 0.50 (0.38–0.67) <0.001
PFS 0.53 (0.40–0.69) <0.001 0.46 (0.38–0.56) <0.001
3. Including only single-arm trials
(excluding PROFILE 1007)
n ¼ 189 vs. n ¼ 384 neff ¼ 85 vs. n ¼ 384
OS 0.48 (0.32–0.72) <0.001 0.63 (0.47–0.83) 0.001
PFS 0.60 (0.46–0.79) <0.001 0.55 (0.45–0.68) <0.001
4. Adjusting for baseline smoking status
(excluding ASCEND-3)
n ¼ 67 vs. n ¼ 557 neff ¼ 43 vs. n ¼ 557
OS 0.54 (0.32–0.93) 0.026 0.43 (0.33–0.54) <0.001
PFS 0.50 (0.34–0.74) <0.001 0.41 (0.35–0.49) <0.001
Note: Ranges in parentheses are 95% conﬁdence intervals. p Values < 0.05 were considered statistically signiﬁcant for comparisons between pooled ceritinib and
crizotinib trials.
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI: conﬁdence interval; Neff, effective sample size after weighting.
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crizotinib-treated patients (55.0% versus 33.9%) and a
lower number of prior regimens (rates with one, two,
or three or more regimens of 48.7%, 28.0%, and
23.3% versus 20.5%, 31.6%, and 47.9%, respectively);
these differences were eliminated by matching. Finally,
in the fourth sensitivity analysis, the proportion of
individuals who had ever smoked was higher among
the ceritinib-treated patients than among the
crizotinib-treated patients before matching (53.7%
versus 33.1%) but was balanced at 33.1% after
matching.Discussion
This study has estimated the comparative efﬁcacy of
ceritinib and crizotinib among patients with previously
treated, crizotinib-naive advanced or metastatic ALK-
positive NSCLC. In the absence of a head-to-head RCT,
an adjusted comparison was made across separate
clinical trial populations. Both before and after adjust-
ment for cross-trial differences, ceritinib was associated
with signiﬁcantly prolonged OS and PFS compared with
crizotinib. In particular, after adjustment, ceritinib was
associated with an additional 17% of patients surviving
for 1 year compared with crizotinib, and with a 5.5-
month increase in median PFS. This level of improve-
ment in median PFS is highly clinically signiﬁcant for
second-line metastatic NSCLC treatment, in which prior
therapeutic improvements in median PFS have ranged
from 0.4 to 4.7 months.13,38
As the present study was a comparison of non-
randomized treatment groups, the baseline similarity ofthose groups is paramount. The fact that all treatment
groups were followed in clinical trial settings, with
regular follow-up visits and imaging, provides an
important initial level of similarity. Multiple steps were
taken to further ensure similarity. First, a review of the
clinical trials indicated highly similar designs and
outcome deﬁnitions. Differences in inclusion and
exclusion criteria were addressed by further sample
selection (i.e., including only previously treated patients
who were naive to ALK-targeted agents). The primary
analysis then adjusted for all patient characteristics that
were available from all of the studied trials, which
included multiple important prognostic factors in ALK-
positive NSCLC (i.e., age, sex, race, ECOG PS, number
of prior regimens, and tumor histologic type). Sensi-
tivity analyses were conducted to adjust for additional
patient characteristics that were available only in sub-
sets of trials, including brain metastases, smoking sta-
tus, and potential for randomization to chemotherapy.
In particular, patients’ race/ethnicity was adjusted for
in the main and sensitivity analyses. The primary
analysis adjusted for the proportion of Asian versus
non-Asian patients whereas the sensitivity analysis
matched on the proportion of white versus nonwhite
patients. These analyses were conducted to ensure
balance in baseline patient race/ethnicity owing to a
potentially higher response rate to crizotinib among
Asian patients demonstrated in previous studies.11,18,37
The overall list of patient characteristics used for
adjustment represents, by design, the characteristics
considered important by the trial investigators and co-
authors, and it was consistent with previously reported
prognostic factors for NSCLC outcomes.11,13,14,18 Longer
1556 Tan et al Journal of Thoracic Oncology Vol. 11 No. 9durations of OS and PFS with ceritinib versus crizotinib
were consistently observed across the primary and
sensitivity analyses. In addition, the changes in estimated
outcomes after adjustments for known baseline prog-
nostic factors were in the expected directions. Adjust-
ment for the higher baseline prevalence of brain
metastases in the ceritinib-treated patients resulted in
improved comparative outcomes for ceritinib, as would
be expected given the known poor prognosis for patients
with brain metastases. Likewise, given the known nega-
tive effect of smoking history on NSCLC clinical outcomes,
the adjustment for the higher baseline prevalence of ex-
and current smokers among the ceritinib-treated patients
contributed, as would be expected, to better comparative
efﬁcacy for ceritinib.
There are inherent limitations to this study. The
absence of publically available patient-level data for the
crizotinib-treated patients necessitated the use of study-
level data to facilitate patient matching. Moreover, as a
comparison of nonrandomized treatment groups from
trials with small to moderate sample sizes, the potential
for confounding due to unobserved or unadjusted dif-
ferences between treatment groups remains an impor-
tant limitation. However, study populations were well
matched in the current analyses in terms of multiple
patient characteristics including age, sex, race, ECOG PS,
number of prior regimens, and histologic type (adeno-
carcinoma versus not). Further, differences in deﬁnitions
of tumor response (i.e., use of RECIST 1.0 versus RECIST
1.1) may have limited comparisons of ORR. In addition,
unrelated to confounding, the OS and PFS data might
have been immature for some of the trials at the time of
the present study.
As new treatment options for ALK-positive NSCLC
emerge, evidence of comparative efﬁcacy is needed to
inform clinical and economic decisions. Direct, random-
ized head-to-head comparisons are the accepted standard
for comparative evidence, yet they are not always avail-
able at the time decisions need to be made. This is
particularly relevant for late-stage oncology settings, such
as advanced or metastatic ALK-positive NSCLC, in which
accelerated access to novel targeted therapies has gener-
ally preceded availability of phase III data. Thus, although
propensity score matching of external controls cannot
replace a direct head-to-head randomized comparison, it
can provide some preliminary insights to comparative
efﬁcacy.11,21–23 In the present study, the comparison of
patients who received ceritinib with external controls
who received crizotinib, in which all patients were fol-
lowed in clinical trial settings and adjustmentsweremade
for multiple patient characteristics, represents the best
available comparative evidence for these treatments as
initial ALK-targeted therapies.Acknowledgments
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